Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Alvotech

33.40 SEK

-3.19 %

Less than 1K followers

ALVO SDB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-3.19 %
-23.05 %
-28.08 %
-36.38 %
-55.37 %
-
-
-
-66.02 %

Alvotech is a biotechnology company that focuses on the development and manufacture of biosimilar medicines. The company's pipeline consists of biosimilar candidates aimed at treating autoimmune diseases, eye diseases, osteoporosis and cancer. The company offers its products to patients all over the world. Alvotech was founded in 2013 and has its headquarters in Reykjavík.

Read more
Market cap
10.85B SEK
Turnover
275.04K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.3.
2026

Annual report '25

7.5.
2026

Interim report Q1'26

20.8.
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Regulatory press release3/4/2026, 8:00 AM

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech
Regulatory press release2/26/2026, 9:00 PM

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release2/11/2026, 4:00 PM

Alvotech Announces Increase in Number of Own Shares

Alvotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release2/5/2026, 8:00 AM

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Alvotech
Regulatory press release2/2/2026, 8:00 AM

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Alvotech
Regulatory press release1/29/2026, 8:00 AM

Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

Alvotech
Regulatory press release1/7/2026, 10:00 PM

Correction: Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release1/6/2026, 8:00 PM

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release1/6/2026, 8:00 PM

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release1/6/2026, 12:15 PM

Alvotech announces planned CEO succession and leadership transition

Alvotech
Regulatory press release12/31/2025, 9:30 PM

Alvotech Secures Term Loan Facility of USD 100 Million

Alvotech
Regulatory press release12/29/2025, 7:40 PM

Changes in company's own shares

Alvotech
Regulatory press release12/22/2025, 8:26 PM

Alvotech’s Financial Calendar for 2026

Alvotech
Regulatory press release12/22/2025, 7:00 AM

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech
Regulatory press release12/19/2025, 8:30 AM

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Alvotech
Regulatory press release12/17/2025, 7:30 AM

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Alvotech
Regulatory press release12/16/2025, 4:48 PM

Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance

Alvotech
Regulatory press release11/24/2025, 10:30 AM

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech
Regulatory press release11/20/2025, 9:00 AM

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech
Regulatory press release11/12/2025, 9:40 PM

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Alvotech
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.